DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...

Sumitomo Mitsui Financial is poised for growth with an improving NIM, a 10% profit boost by FY 2026. Click here to read why ...

Poxel eligible for royalties equaling 10% of all TWYMEEG ® net sales for 2024 and a one-time sales-based payment of JPY 500 million (EUR 3.1 million 3). Beyond 2024, Poxel expects to receive ...

Poxel eligible for royalties equaling 10% of all TWYMEEG ® net sales for 2024 and a one-time sales-based payment of JPY 500 million (EUR 3.1 million 3). Beyond 2024, Poxel expects to receive ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Analysts fell to the sidelines weighing in on Sumitomo Dainippon Pharma Co (DNPUF – Research Report) and Sanofi (SNYNF – Research Report) with ...

Japan is one of the Asian countries that is aging quickly. In June 2019, Sumitomo Dainippon Pharma Co. Ltd. modified its contract with Healios K.K. for joint development initiatives and other ...

UK-based Exscientia has been working with Japanese pharma Sumitomo Dainippon Pharma (DSP) on the drug for obsessive-compulsive disorder (OCD), and the trial aims to measure its efficacy.

New York, USA, Jan. 22, 2025 (GLOBE NEWSWIRE) -- 5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...

The past two years have been punishing for the biotech and pharma space. As Wall Street chased the artificial-intelligence boom, drugmakers were left behind, with pharma stocks trading at a ...